ASCO GU 2025: CLARIFY: PET Using 64Cu-SAR-bisPSMA in Patients with High-Risk Prostate Cancer Prior to Radical Prostatectomy—A Phase 3 Diagnostic Performance Study
https://www.urotoday.com/conference-highlights/asco-gu-2025/asco-gu-2025-prostate-cancer/158214-asco-gu-2025-cobra-assessment-of-the-efficacy-of-64cu-sar-bispsma-using-histopathology-as-reference-standard-in-patients-with-biochemical-recurrence-of-prostate-cancer-following-definitive-therapy.html
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.38 |
Change
-0.280(6.01%) |
Mkt cap ! $1.628B | |||
| Open | High | Low | Value | Volume |
| $4.62 | $4.65 | $4.30 | $18.54M | 4.185M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 14980 | $4.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.39 | 2500 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |